Inhaled COPD Therapeutics


Chart_Collage_160   Published June 2014  •  Catalog no. CPD259K  •  Price US $3,850


COPD is not one but a family of conditions, each with its own etiology and treatment challenges. Chronic bronchitis is the inflammation and eventual scarring of the lining of the bronchial tubes. Oral COPD inhalers, half of which are two-drug combination products, include design elements that attempt to address the unique and challenging treatment factors associated with COPD. The resulting devices are user-friendly and incorporate designed-in safety features, and in the process support the parallel goal of improved compliance. While not curative, these inhalable drug products provide patients with symptomatic relief while reducing the morbidity associated with this progressive disease.

Bar_GraphInhaled COPD Therapeutics Report Prospectus (Download PDF)

Blue document Inhaled COPD Therapeutics Report Order Form (Download PDF)


Highlights

• Analyzes therapeutic drugs and pipeline candidates delivered via oral inhalers for treating COPD
• Assesses inhalation device technology for commercial and development-stage devices, and evaluates product technology issues and evolving market factors
• Provides detailed assessments of inhaled drug targeted disease segments, growth prospects and market potential
• Provides market data and forecasts for inhaled COPD therapeutic drugs to 2020
• Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
• Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners


Summary of Contents

Executive Summary

COPD Therapeutics Market Dynamics

Devices, Formulations and Market Evolution
Established Therapeutic Targets
Competing Dosage Forms
Prescribing Trends
Therapeutic Strategies
Factors Driving Growth

COPD Technology & Product Development Factors

Drug Formulations & Formulation Technologies
Inhalation Device Design Factors
Dry Powder Inhalers
Metered Dose Inhalers
Nebulizers
Dose Reproducibility
Active Compound Stability
Emerging Device Technologies

COPD Inhaler Design Factors

Novel Formulation Technology
Patient-friendly Administration/Coaching Technology
User Confirmation/Feedback/Disease Management
Embedded Electronics
Combination (multidrug) Inhalers

Inhaled COPD Product Analysis, Market Data & Forecasts

Anticholinergics
Anticholinergic/SABA
Antocholinergic/LABA
ICS/LABA
LABA
Other Important/Emerging Drug Classes

Market Factors

Regulations and Standards
Clinical Trials
Healthcare Economics
Managed Care and Payor Initiatives

Company Profiles